Numeric Investors LLC raised its stake in Genomic Health, Inc. (NASDAQ:GHDX) by 53.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 89,999 shares of the medical research company’s stock after purchasing an additional 31,423 shares during the quarter. Numeric Investors LLC owned 0.26% of Genomic Health worth $2,929,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Genomic Health by 6.8% in the second quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock worth $54,379,000 after purchasing an additional 106,452 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Genomic Health by 10.9% in the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock worth $26,473,000 after purchasing an additional 80,100 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Genomic Health by 10.0% in the first quarter. Loomis Sayles & Co. L P now owns 584,515 shares of the medical research company’s stock worth $18,406,000 after purchasing an additional 53,344 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Genomic Health by 3.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 497,340 shares of the medical research company’s stock worth $16,189,000 after purchasing an additional 14,665 shares during the last quarter. Finally, Eagle Asset Management Inc. raised its stake in shares of Genomic Health by 18.4% in the second quarter. Eagle Asset Management Inc. now owns 379,473 shares of the medical research company’s stock worth $12,351,000 after purchasing an additional 58,920 shares during the last quarter. 88.90% of the stock is owned by hedge funds and other institutional investors.

Several analysts have recently commented on the company. Zacks Investment Research downgraded Genomic Health from a “hold” rating to a “sell” rating in a research note on Wednesday. Canaccord Genuity reissued a “buy” rating and issued a $35.00 price objective on shares of Genomic Health in a research note on Wednesday, September 27th. Jefferies Group LLC reissued a “hold” rating and issued a $33.00 price objective on shares of Genomic Health in a research note on Thursday, September 14th. Cowen and Company reissued a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research note on Friday, September 1st. Finally, BidaskClub raised Genomic Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Two analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $31.83.

Genomic Health, Inc. (NASDAQ:GHDX) opened at 32.07 on Friday. The stock has a 50 day moving average price of $31.20 and a 200 day moving average price of $31.61. Genomic Health, Inc. has a 12-month low of $26.37 and a 12-month high of $33.97. The company’s market capitalization is $1.11 billion.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The firm had revenue of $85.50 million during the quarter, compared to analysts’ expectations of $86.08 million. During the same quarter in the previous year, the firm earned ($0.18) earnings per share. Genomic Health’s revenue was up 4.3% on a year-over-year basis. On average, analysts expect that Genomic Health, Inc. will post ($0.02) EPS for the current year.

In other Genomic Health news, insider James J. Vaughn sold 8,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $30.59, for a total transaction of $244,720.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction on Tuesday, July 11th. The shares were sold at an average price of $32.53, for a total transaction of $162,650.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,174 shares of company stock valued at $1,132,171. Company insiders own 46.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/numeric-investors-llc-has-2-93-million-stake-in-genomic-health-inc-ghdx/1612323.html.

Genomic Health Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.